



## Lecanemab for Early Alzheimer’s Disease: Effectiveness and Value

Friday • March 17, 2023 • 9:00 AM – 3:00 PM PT

Virtual Event – Zoom Webinar

Registration: [https://us02web.zoom.us/webinar/register/WN\\_qXKpm6YyT3qDitH6Tj-V-A](https://us02web.zoom.us/webinar/register/WN_qXKpm6YyT3qDitH6Tj-V-A)

Time (PT)	Activity
9:00am – 9:20am	<b>Meeting Convened and Opening Remarks</b> Steven D. Pearson, MD, MSc President, ICER
9:20am – 10:00am	<b>Presentation of the Clinical Evidence</b> Grace Lin, MD, MAS Medical Director for Health Technology Assessment, ICER Associate Professor of Medicine and Health Policy, UCSF
10:00am – 10:40am	<b>Presentation of the Economic Model</b> Melanie Whittington, PhD, MS Director of Health Economics, ICER
10:40am – 11:10am	<b>Public Comments and Discussion</b>
11:10am – 11:50am	<b>Lunch Break</b>
11:50am – 12:50pm	<b>CTAF Vote on Clinical Effectiveness and Value</b>
12:50pm – 1:00pm	<b>Break</b>
1:00pm – 2:30pm	<b>Policy Roundtable</b>
2:30pm – 3:00pm	<b>Reflections from CTAF</b>
3:00pm	<b>Meeting Adjourned</b>

ICER Staff and Consultants*	
<b>Kelsey Gosselin, MA</b> , Program Manager, ICER	<b>David Rind, MD, MSc</b> , Chief Medical Officer, ICER
<b>Serina Herron-Smith, BA</b> , Associate Research Manager, ICER	<b>Melanie Whittington, PhD, MS</b> , Director of Health Economics, ICER
<b>Yasmine Kayali, BA</b> , Program Coordinator, ICER	<b>Abigail Wright, PhD, MSc</b> , Senior Research Lead, Evidence Synthesis, ICER
<b>Grace Lin, MD</b> , Medical Director for Health Technology Assessment, ICER	

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Participating Members of CTAF*	
<b>Felicia Cohn, PhD, HEC-C</b> Bioethics Director, Kaiser Permanente Orange County	<b>Annette Langer-Gould, MD, PhD</b> Regional Lead for Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente
<b>Robert Collyar</b> Patient Advocate	<b>Sei Lee, MD, MAS</b> Professor of Medicine, University of California San Francisco
<b>Sanket Dhruva, MD, MHS</b> Assistant Professor of Medicine, University of California San Francisco	<b>Joy Melnikow, MD, MPH</b> Professor emeritus, University of California Davis
<b>Rena Fox, MD</b> Professor of Medicine, University of California San Francisco	<b>Elizabeth Murphy, MD, DPhil</b> Professor of Medicine, University of California San Francisco
<b>Kim Gregory, MD, MPH</b> Vice Chair OBGYN, Division Director Maternal Fetal Medicine, Cedars-Sinai	<b>Kathryn Phillips, PhD</b> Professor, University of California San Francisco
<b>Paul Heidenrich, MD</b> Professor of Medicine, Stanford University	<b>Rita Redberg, MD, MSc</b> Professor of Medicine, University of California San Francisco
<b>Jeffrey Hoch, MA, PhD</b> Professor, University of California Davis	<b>Tony Sowry, BA</b> Patient Advocate and Lead Volunteer, California, National Patient Advocate Foundation
<b>Jeffrey Klingman, MD</b> Chair of Neurology, Kaiser Permanente Northern California	

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
<b>Victor Henderson, MD, MS</b> , Professor of Epidemiology and Population Health and of Neurology, Stanford University	No conflicts to disclose.
<b>Jason Karlawish, MD</b> , Professor of Medicine, University of Pennsylvania	Dr. Karlawish has received manufacturer support of research in the clinical area of this meeting. Dr. Karlawish has served as a site investigator for clinical trails sponsored by Eli Lilly & Co. and Biogen Inc.
<b>Doreen Monks, RN, MSN</b> , Patient Advocate	No conflicts to disclose.
<b>Russ Paulsen, MA</b> , Chief Operating Officer, UsAgainstAlzheimer's	UsAgainstAlzheimer's receives funding from companies, including less than 25% from Eisai Co.
<b>Gail Ryan, PharmD</b> , Director of Pharmaceutical Transformation, Point32Health	Dr. Ryan is a full-time employee of Point32Health.
<b>Amir A. Tahami, MD, MSc, Ph.D</b> , Global Value & Access Head, Alzheimer's Disease and Brain Health, Eisai Co.	Dr. Tahami is a full-time employee of Eisai Co., Ltd.
<b>Susan Wojcicki, PharmD, BCOP</b> , Interim Director, Humana Pharmacy Solutions Clinical Drug Evaluation & Policy Strategies, Humana	Dr. Wojcicki is a full-time employee of Humana.